Investigation Report on China’s Hydroxychloroquine Market, 2021-2025

admin — Sat, 10 Apr 2021 06:25:25 +0000

Hydroxychloroquine is commonly used to prevent and treat malaria. The pharmacokinetics of hydroxychloroquine is similar to that of chloroquine. It can be rapidly absorbed in the gastrointestinal tract and excreted in the kidneys. Hydroxychloroquine is also used in the treatment of rheumatoid arthritis, lupus erythematosus, and delayed skin lesions purpura.

The sales of hydroxychloroquine in the Chinese market have been rising steadily, from CNY 258 million in 2016 to CNY 343 million in 2020, with a CAGR of 7.34% from 2016 to 2020. In 2020, China’s sales of hydroxychloroquine were CNY 343 million, a slight increase of 0.71% than 2019.

The market demand for hydroxychloroquine in China is relatively large. There are two companies approved for manufacturing hydroxychloroquine, namely Shanghai Zhongxi Pharmaceutical Co., Ltd. and Sanofi-aventis Ireland Ltd. Shanghai Zhongxi Pharmaceutical Co., Ltd. has a larger sales market share with lower prices advantage. In 2020, the sales amount of Shanghai Zhongxi Pharmaceutical is as high as CNY 233 million, and the market share is 68.05%.

Hydroxychloroquine has been tried out in search for its effectiveness of prevention and treatment for coronavirus diseases in the first half of 2020. In March 2020, the Shanghai Municipal Health Commission in China recommended that hydroxychloroquine be used to treat mild to moderate new coronavirus diseases. The preliminary results of clinical studies in China and France showed that hydroxychloroquine is effective and safe. On March 28, 2020, the U.S. Food and Drug Administration issued Emergency Use Authorization (EUA) for use of Hydroxychloroquine Sulfate for treatment of 2019 Coronavirus disease. However, on July 4, 2020, the World Health Organization announced that it would stop the hydroxychloroquine trial on the grounds because “the mortality rate of hospitalized patients with coronary disease could not be relieved during the trial”. In August 2020, the “Covid-19 Diagnosis and Treatment Plan (Trial Eighth Edition)” issued by the National Health Commission of China stated that “hydroxychloroquine or combined use with azithromycin is not recommended.”

The sales volume increased in the short term when used in the experimental prevention and treatment at the beginning of 2020. It is predicted that its sales will gradually return to the original level, that is, it is mainly used for the treatment of malaria and rheumatoid arthritis.
Topics Covered:
-The impact of COVID-19 on China’s hydroxychloroquine market
-Market size of hydroxychloroquine in China
-Major R hydroxychloroquine manufacturers in China
-Prices of hydroxychloroquine in China
-Major factors affecting the development of China’s hydroxychloroquine market
-Prospect of China’s hydroxychloroquine market

The post Investigation Report on China’s Hydroxychloroquine Market, 2021-2025 first appeared on CRI Report.

Investigation Report on Chinese Hydroxychloroquine(HCQ) Market, 2020-2024

admin — Tue, 20 Oct 2020 02:29:43 +0000

Description
Hydroxychloroquine(HCQ) is an antimalarial drug. It treats malaria by killing the parasites that cause the disease. Hydroxychloroquine was listed in the United States in 1955, and the original research drug manufacturer was Sanofi. Hydroxychloroquine has been listed in Canada, France, Germany, Australia, China, Japan and other countries, and many companies worldwide have produced generic drugs of hydroxychloroquine. The indications for hydroxychloroquine include malaria, rheumatoid arthritis, lupus erythematosus, etc.
According to CRI, in 2019, the global production volume of hydroxychloroquine was approximately 300 tons. Among them, India produced about 110 tons, ranking first. The total production volume in Europe is about 80 tons, of which Sanofi’s production is about 60 tons, and Novartis’s Sandoz production is about 20 tons. Hydroxychloroquine produced in Europe is mainly sold to Europe and Asia. China’s production is about 55 tons, most of which are sold in China. In 2020, China exported about 20 tons of hydroxychloroquine APIs. The hydroxychloroquine preparations on the global market are basically hydroxychloroquine sulfate preparations. In 2019, the world’s most important hydroxychloroquine market was the United States, which consumed approximately 90 tons of hydroxychloroquine APIs, and the main source of imports was India. India is the world’s second largest market, consuming approximately 60 tons of APIs. The Chinese market consumes approximately 35 tons of APIs.
It is not fully understood how this drug works to treat lupus erythematosus or rheumatoid arthritis. However, it is believed that this drug affects how your immune system works, which may be a benefit in lupus erythematosus and rheumatoid arthritis.
On March 28, 2020, FDA issued an EUA to allow hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile (SNS) to be distributed and used for hospitalized COVID-19 patients. An EUA allows for an unapproved drug to be prescribed in limited and controlled ways during an emergency such as a pandemic.
There is a lot of controversy over whether hydroxychloroquine can prevent, treat, or cure COVID-19, the illness caused by the novel coronavirus. Some small studies in China and Europe were initially promising, however, other studies have found that hydroxychloroquine offers no benefit or may even be harmful to patients infected with the coronavirus. There are many more studies underway, but the best available evidence suggests that hydroxychloroquine is not effective in the treatment and prevention of COVID-19, and the potential benefits of the drug do not outweigh the known and potential risks. As a result, on June 15, 2020, the FDA has revoked their earlier issue of an Emergency Use Authorization (EUA) for hydroxychloroquine.
According to CRI’s market research, as of the end of 2020, only two companies in the Chinese market have been approved for hydroxychloroquine, namely Sanofi, the original research drug manufacturer of hydroxychloroquine, and Shanghai Zhongxi Pharmaceutical Co., Ltd., a generic drug manufacturer.
According to CRI’s market research, in 2019, the sales value of Hydroxychloroquine reached CNY340.3 million(US$49.3 million) in China. As Shanghai Zhongxi Pharmaceutical Co., Ltd.’s hydroxychloroquine product has a certain price advantage, it has occupied a major share of the Chinese market. In 2019, based on sales value, Shanghai Zhongxi Pharmaceutical Co., Ltd.’s hydroxychloroquine accounted for 69% of the Chinese market.
As some studies have shown that hydroxychloroquine may have a certain effect on COVID-19, the demand for hydroxychloroquine in the global market will increase in 2020-2021. According to CRI’s market research, from January to August 2020, China’s exports of hydroxychloroquine increased by approximately 20% year-on-year. It is expected that China’s domestic hydroxychloroquine market sales will continue to grow from 2020 to 2024, and China’s hydroxychloroquine export value will also continue to rise.

Topics Covered:
– The impact of the COVD-19 epidemic on the hydroxychloroquine market
-Development environment of Chinese Hydroxychloroquine market
-Sales value and volume of Hydroxychloroquine in China 2015-2019
-Sales value and volume of Hydroxychloroquine in Different Regions of China 2015-2019
-Prices of Hydroxychloroquine in China 2015-2019
-Prices of Sanofi’s Hydroxychloroquine(Plaquenil) in Different Regions of China 2015-2019
-Prices of Shanghai Henlius Biotech, Inc.’s Hydroxychloroquine(Fenle) in Different Regions of China 2015-2019
-Progress of Generic Hydroxychloroquine in China
-Prospects of Chinese Hydroxychloroquine Market, 2020-2024

The post Investigation Report on Chinese Hydroxychloroquine(HCQ) Market, 2020-2024 first appeared on CRI Report.

Hydroxychloroquine – CRI Report

Investigation Report on China’s Hydroxychloroquine Market, 2021-2025

Investigation Report on Chinese Hydroxychloroquine(HCQ) Market, 2020-2024